Skip to main content
OpenTrials
Completed

NCT Number: NCT07505589

Pacing In Organ Donors (the POD Trial)

The goal of this clinical trial is to test the feasibility of pacing the phrenic nerve to stimulate the diaphragm in order to improve the lung function in brain dead organ donors. The main questions it aims to answer are:

* Proof of concept and feasibility * Can lung function be improved in lungs that have been disqualified for donation

Participants will have an AeroPace catheter inserted and will be paced on every breath up to the time of organ donation.

Completed

Looking for future studies?

Notify Me

Key information

Age range

19 year–100 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Royal Columbian Hospital

New Westminster, B.C., V3L 3W7, Canada

About this study

Single-center, single-arm, proof-of-concept trial. Up to twenty (20) subjects on mechanical ventilation who are determined to be brain dead and whose lungs are declined for donation based on a PaO2/FiO2 ratio < 300 mmHg will be enrolled. Subjects may also be enrolled in the study at the request of the donation team if the lungs are accepted for donation but of marginal quality. Consent from the temporary substitute decision maker (TSDM) will be obtained for (i) organ donation and (ii) for study participation.

All subjects will receive Lungpacer AeroPace Protect System catheter-based transvenous phrenic nerve stimulation (LAPS-PNS) with lung-protective mechanical ventilation and standard of care for transplant donors. Insertion of the AeroPace Catheter will be conducted as soon as possible after the determination of lung transplant ineligibility. LAPS-PNS will be titrated with the ventilator to provide a contribution to the work of breathing sufficient to retain diaphragm activation.

Measurements to determine the effects of LAPS-PNS on donor lung function and physiology will be conducted until the time of organ donation. An esophageal-gastric manometer and electrical impedance tomography (EIT) unit will be utilized, respectively, to assess transdiaphragmatic pressure and lung volume distribution. Data collected for brain dead donors admitted to the same ICU over the 2 years preceding the study start who did not qualify for lung donation will serve as an unmatched comparator group.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Designated as brain dead according to BC provincial guidelines, and
  • Are 19 years or older, and
  • Are mechanically ventilated, and
  • TSDM consented for organ donation, and
  • TSDM consented to study participation, and
  • Accepted by BC transplant team to donate at least 1 organ system, and
  • Declined by BC transplant team for lung donation based on hypoxia with the PaO2/FiO2ratio < 300 mmHg or other criterion that precludes lung donation as requested by the organ donation team.

Exclusion criteria

  • Greater than 8 hours from time declined for lung donation and initiation of LAPS-PNS,
  • Inability to place a central venous catheter in the left internal jugular or left subclavian vein,
  • Neuromuscular disease (e.g., Amyotrophic Lateral Sclerosis, Guillain-Barre),
  • Previous phrenic nerve injury,
  • Spinal cord injury above the 6th cervical spine level,
  • Implanted electronic cardiac or neurostimulation device in situ
  • 2nd or 3rd degree heart block on at least 2 EKGs conducted during routine care,
  • Treating physician deems enrollment not clinically appropriate for other reason

Treatment and study plan

Lungpacer AeroPace catheter and device

Device

Diaphragm neurostimulation device for phrenic nerve pacing during mechanical ventilation.

Primary outcomes

  1. Change in PaO2/FiO2 ratios from baseline

    Time frame: ABG measurements will be taken every 6 hours from enrolment until study endpoint for each participant.

    PaO2/FiO2 ratio measured from arterial blood gas values.

  2. Number of safety events

    Time frame: Under continuous observation from subject enrolment until study endpoint (organ donation), an average of 40 hours.

    Determine whether any unexpected, or device-related or procedure-related complications occur in brain dead subjects. Standardized checklists will be developed to track safety events including arrhythmia, bradycardia, discomfort, hypertension/hypotension, inappropriate stimulation, pain or discomfort, phrenic nerve damage or injury, and syncope.

Secondary outcomes

  1. Determine percent of eligible ventilator breaths delivered with LAPS-PNS

    Time frame: Under continuous observation from subject enrolment until study endpoint (organ donation), an average of 40 hours.

    Eligible breaths are defined as those breaths in which PNS is not precluded by clinical care/procedures or subject transport.

  2. Change in distribution of ventilation using Electrical Impedance Tomography (EIT)

    Time frame: Under continuous observation from subject enrolment until study endpoint (organ donation), an average of 40 hours.

    Measured in impedance units, percentage change from baseline

  3. Total vasopressor use (mg/mL) during LAPS-PNS use

    Time frame: Under continuous observation from subject enrolment until study endpoint (organ donation), an average of 40 hours.

  4. Total fluid administration (mL/kg) during LAPS-PNS dose

    Time frame: Under continuous observation from subject enrolment until study endpoint (organ donation), an average of 40 hours.

  5. Change in kidney function during LAPS-PNS dose from baseline

    Time frame: Under continuous observation from subject enrolment until study endpoint (organ donation), an average of 40 hours.

    Measures of urine output (mL/kg) and creatinine (umol/L)

  6. Average vital sign recording during LAPS-PNS dose

    Time frame: Under continuous observation from subject enrolment until study endpoint (organ donation), an average of 40 hours.

    Collection variables include temperature (degrees celsius), heart rate (bpm), SBP/DBP, MAP, RR (breaths/min)

Sponsors and collaborators

Lead sponsor

Fraser Health

Other

Collaborators

  • Lotte & John Hecht Memorial Foundation
  • Lungpacer Medical Inc.

Registry information

Official study title

Diaphragm Neurostimulation to Improve Lung Function in Brain Dead Donors

Acronym: POD

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Apr 1, 2026
Registry last updated
Apr 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.